-
Study aim
-
To determine and compare the efficacy of an innovative chitosan nanofiber dressing versus routine hospital dressing on wound healing, postoperative pain, and surgical site infection (SSI) following elective primary cesarean section.
-
Design
-
A randomized, parallel-group, single-blind, controlled clinical trial, phase 2-3, on 68 elective cesarean mothers.
-
Settings and conduct
-
This single-blind clinical trial will be conducted at a university hospital of Mashhad University of Medical Sciences. Eligible elective cesarean mothers are randomized (1:1) into intervention (chitosan dressing) or control groups using variable block randomization. Patients are blinded to the dressing applied under anesthesia in the operating room.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria: Written informed consent, maternal age 18 to 40 years, gestational age 37 to 41 full weeks, elective primary cesarean section with transverse incision, body mass index (BMI) under 35, and absence of systemic diseases affecting wound healing or immunosuppressive medications.
Exclusion Criteria: severe intraoperative bleeding requiring blood transfusion, surgery duration exceeding 90 minutes, non-cooperation with follow-up, and need for wound re-exploration or secondary abdominal surgery during the recovery period.
-
Intervention groups
-
In the intervention group, immediately following cesarean skin closure in the operating room, the surgical incision is covered with an innovative biocompatible chitosan nanofiber dressing.
-
Main outcome variables
-
pain, wound healing, and surgical site infection